Literature DB >> 9209530

Influence of brachytherapy applicators geometry on dose distribution in cervical cancer.

E Senkus-Konefka1, A Kobierska, J Jassem, K Serkies, A Badzio.   

Abstract

AIM: Although the relationship between the dose delivered to adjacent organs (urinary bladder and rectum) and the frequency and severity of treatment complications has been reported in many series, the factors influencing pelvic dose distribution are not well defined. The aim of the study was to assess retrospectively the influence of the size of cervical cancer brachytherapy applicators (ovoids and uterine tandems) on pelvic dose distribution and the impact of various therapy-dependent factors on patient anatomy and on dose distribution in particular applications. PATIENTS AND
METHOD: The subject of this study were 356 cervical cancer patients treated with Selectron LDR as a part of their radical radiotherapy. Analysed factors included preceding external beam radiotherapy (EBRT) or brachytherapy applications, use of general anaesthesia for application and the system of pellet loading.
RESULTS: Significant correlation was found between the size of applicators and doses to bladder, rectum and points B: larger vaginal applicators produced lower dose in bladder and rectum and higher dose in point B (all p < 0.0001), longer uterine tandems produced lower dose in rectum and higher dose in point B (both p < 0.0001). Significant decrease in the frequency of use of large applicators (ovoids: p < 0.0001, tandems: p = 0.055) and worsening of dose distribution, i.e. higher doses to critical organs (respectively: bladder p = 0.0012, rectum p = 0.02) and lower point B dose (p = 0.0001) were observed at consecutive brachytherapy applications. Similar situation occurred in patients, who received EBRT prior to brachytherapy (ovoids: p < 0.001, tandem: p = 0.04, bladder dose: p = 0.009, rectal dose: p = 0.073, point B dose: p = 0.059). Vaginal applicators were larger (p = 0.026) and the dose distribution was better (bladder: p = 0.023, rectum: p = 0.002, point B: p = 0.0001) in patients who had their insertions performed under general anaesthesia. The comparison of 2 consecutively used systems of pellet loading revealed more favourable dose distribution: lower dose for bladder (p = 0.014) and higher dose for point B (p < 0.0001) for the system, which utilised more sources in ovoids and in the distal part of the uterine tandem, in spite of more frequent use of smaller applicators in this group of patients. In multivariate analysis ovoid size was related to preceding external beam radiotherapy (p = 0.025). Uterine tandem length was dependent on the number of preceding intracavitary applications (p < 0.001) and preceding external beam radiotherapy (p = 0.007). Bladder dose was related to preceding brachytherapy (p = 0.011) and the pattern of pellet loading (p = 0.031). Rectal dose was dependent only on the use of general anaesthesia during application (p = 0.001) and point B dose was dependent on the pattern of pellet loading (p < 0.001) and marginally-on the use of preceding external beam radiotherapy (p = 0.06).
CONCLUSIONS: The results of this study allow for identification of treatment-related factors determining pelvic dose distribution in cervical cancer brachytherapy and may potentially enable optimisation of this distribution in particular clinical situation.

Entities:  

Mesh:

Year:  1997        PMID: 9209530     DOI: 10.1007/BF03038915

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   4.033


  26 in total

1.  Treatment of cancer of the cervix uteri, a revised Manchester method.

Authors:  M TOD; W J MEREDITH
Journal:  Br J Radiol       Date:  1953-05       Impact factor: 3.039

2.  Dosimetric analysis in brachytherapy of carcinoma of the cervix.

Authors:  L Krishnan; E P Cytacki; C D Wolf; E K Reddy; L S Gemer; P G Giri; S R Smalley; R G Evans
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-04       Impact factor: 7.038

3.  The ICRU recommendations for reporting intracavitary therapy in gynaecology and the Manchester method of treating cancer of the cervix uteri.

Authors:  J M Wilkinson; T P Ramachandran
Journal:  Br J Radiol       Date:  1989-04       Impact factor: 3.039

4.  Morbidity following low-dose-rate selectron therapy for cervical cancer.

Authors:  E Sherrah-Davies
Journal:  Clin Radiol       Date:  1985-03       Impact factor: 2.350

5.  Anatomic variation of gynecologic brachytherapy prescription points.

Authors:  P W Grigsby; A Georgiou; J F Williamson; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-10-20       Impact factor: 7.038

6.  Positional stability of sources during low-dose-rate brachytherapy for cervical carcinoma.

Authors:  B W Corn; J M Galvin; E M Soffen; G Henze; F Schwaibold
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-06-15       Impact factor: 7.038

7.  Rectal complication after remote afterloading intracavitary therapy for carcinoma of the uterine cervix.

Authors:  T Teshima; M Chatani; K Hata; T Inoue; T Inoue; T Suzuki
Journal:  Strahlentherapie       Date:  1985-06

8.  Routine clinical estimation of rectal, rectosigmoidal, and bladder doses from intracavitary brachytherapy in the treatment of carcinoma of the cervix.

Authors:  D E Cunningham; J A Stryker; D E Velkley; C K Chung
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-05       Impact factor: 7.038

9.  Cancer of the uterine cervix: dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment.

Authors:  H Pourquier; J B Dubois; R Delard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-11       Impact factor: 7.038

10.  Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium.

Authors:  A D Hamberger; A Unal; D M Gershenson; G H Fletcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-03       Impact factor: 7.038

View more
  3 in total

1.  A study on the variation of bladder and rectal doses with respiration in intracavitary brachytherapy for cervix cancer.

Authors:  Ramachandran Prabhakar; Pandjatcharam Jagadesan; Kunhi P Haresh; Singh Karuna; Pramod Kumar Julka; Goura Kishor Rath
Journal:  J Contemp Brachytherapy       Date:  2010-04-01

2.  A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes.

Authors:  Zahra Siavashpour; Mahmoud Reza Aghamiri; Ramin Jaberi; Naser ZareAkha; Hamid Reza Dehghan Manshadi; Christian Kirisits; Mahbod Sedaghat
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

3.  On the accuracy of dose prediction near metal fixation devices for spine SBRT.

Authors:  Zhangkai J Cheng; Regina M Bromley; Brad Oborn; Martin Carolan; Jeremy T Booth
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.